Skip to main content

Systemic Mastocytosis

2
Pipeline Programs
2
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AB Science
AB ScienceFrance - Paris
1 program
1
masitinibPhase 3Small Molecule5 trials
Active Trials
NCT04622865Unknown200Est. Dec 2023
NCT03556956Completed219Est. Dec 2020
NCT01694277Completed258Est. Dec 2020
+2 more trials
Sandoz
SandozAustria - Kundl
1 program
1
RAD001Phase 21 trial
Active Trials
NCT00449748Completed10Est. Oct 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AB Sciencemasitinib
AB Sciencemasitinib
AB Sciencemasitinib
AB Sciencemasitinib
AB Sciencemasitinib
AB Sciencemasitinib
SandozRAD001
AB Sciencemasitinib
AB Sciencemasitinib
AB Sciencemasitinib
AB Sciencemasitinib

Clinical Trials (11)

Total enrollment: 1,306 patients across 11 trials

NCT01694277AB Sciencemasitinib

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Start: Apr 2012Est. completion: Dec 2020258 patients
Phase 3Completed
NCT01280565AB Sciencemasitinib

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Start: Jan 2011Est. completion: Aug 2019134 patients
Phase 3Terminated
NCT00812240AB Sciencemasitinib

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Start: Jan 2009Est. completion: Jul 2018335 patients
Phase 3Terminated
NCT03556956AB Sciencemasitinib

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Start: Jul 2015Est. completion: Dec 2020219 patients
Phase 2/3Completed
NCT04622865AB Sciencemasitinib

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Start: Jun 2020Est. completion: Dec 2023200 patients
Phase 2Unknown
NCT01506336AB Sciencemasitinib

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Start: Oct 2008Est. completion: Apr 201244 patients
Phase 2Completed
NCT00449748SandozRAD001

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Start: Apr 2007Est. completion: Oct 200910 patients
Phase 2Completed
NCT00913432AB Sciencemasitinib

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

Start: Mar 2007Est. completion: Sep 201020 patients
Phase 2Completed
NCT01266369AB Sciencemasitinib

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

Start: Feb 2007Est. completion: May 201021 patients
Phase 2Completed
NCT00998751AB Sciencemasitinib

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Start: Jun 2005Est. completion: Jun 201330 patients
Phase 2Completed
NCT01450488AB Sciencemasitinib

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Start: Jun 2005Est. completion: Jan 201035 patients
Phase 2Completed

Related Jobs

Area Business Manager, Allergy Immunology, Jacksonville, FL

SanofiSanofi
Jacksonville, FL
3w ago

Area Business Manager - Hematology/Oncology - Spring Valley/Fresno, CA

SanofiSanofi
Los Angeles, CA
3w ago
$125K - $209K/yr

Rare Hematology Area Business Manager - Allergy/Immunology, Long Island

SanofiSanofi
Columbus, OH; Indianapolis, IN; Cleveland, OH
3w ago

Area Business Manager – Allergy/Immunology – Atlanta, GA

SanofiSanofi
Atlanta, GA
3w ago

Area Business Manager - Hematology/Oncology – South Atlanta, GA

SanofiSanofi
Atlanta, GA
3w ago

Area Business Manager, Allergy Immunology, Orlando, FL - Fort Lauderdale, FL

SanofiSanofi
Orlando, FL; Ft Lauderdale, FL
3w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.